Screening data were analysed for quality control, and Z prime scores were calculated for each plate using the Dotmatics Studies software (all Z prime scores were greater than 0.5). Each plate contained eight samples negative and positive controls (siNTC, siAS). The median of the eight negative controls on each plate was used to calculate sample values for the siRNA probes (value = (median(siNTC) − SAMPLE) / (median(siNTC)) × 100). Mean of three experiments was calculated for each cell line, each gene, each sequence and each condition (DMSO, DCT). Window sizes were calculated across all genes and sequences in a given cell line, and mean plus two standard deviations was used as a cutoff to determine significant sequences. Genes with two or more significant sequences were considered significant in that cell line. Furthermore, combination indices (CI) were calculated using the Bliss independence model, for each gene, sequence and experiment in each cell line. For each cell line, we plotted the distribution of all CI scores and determined the 0.05 quantile in order to obtain a significance value relative to the screening data.
Incucyte data were downloaded as percent confluence in phase and green channels (CytoxGreen). Mean of technical replicates (three or more wells per condition, two images per well per scan) was used for all calculations and data were normalized by the confluency at time of drug addition for all conditions. Relative GI curves were then calculated as DCT/DMSO and plotted using mean of experiments and error of means. Significant differences between groups of curves were determined by calculating AUC using the trapezoidal rule for each curve, followed by Student’s T-test.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.